CD274 and non-small cell lung carcinoma: In advanced, treatment-naïve NSCLC, PD-L1 expression by immunohistochemistry has been used as the primary biomarker for selecting patients that are more likely to be suitable for receiving ICI, mainly anti-PD(L)1 inhibitors.